Litchfield Hills Research Estimates ADIL FY2025 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Stock analysts at Litchfield Hills Research upped their FY2025 earnings per share (EPS) estimates for Adial Pharmaceuticals in a research note issued on Thursday, February 12th. Litchfield Hills Research analyst T. O’neill now anticipates that the company will post earnings per share of ($7.92) for the year, up from their prior forecast of ($12.00). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q4 2025 earnings at ($1.94) EPS, Q1 2026 earnings at ($1.77) EPS, Q2 2026 earnings at ($1.86) EPS, Q3 2026 earnings at ($1.95) EPS, Q4 2026 earnings at ($1.95) EPS and FY2026 earnings at ($7.55) EPS.

Several other research firms have also recently commented on ADIL. Weiss Ratings restated a “sell (e+)” rating on shares of Adial Pharmaceuticals in a research note on Wednesday, January 21st. UBS Group set a $8.00 price objective on shares of Adial Pharmaceuticals in a research report on Wednesday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $22.75.

Adial Pharmaceuticals Price Performance

Shares of NASDAQ ADIL opened at $2.85 on Monday. The stock has a fifty day moving average price of $5.58 and a 200 day moving average price of $7.77. Adial Pharmaceuticals has a 1-year low of $2.70 and a 1-year high of $32.50. The company has a market cap of $3.16 million, a PE ratio of -0.15 and a beta of 1.26.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its earnings results on Thursday, November 13th. The company reported ($2.00) earnings per share for the quarter, beating the consensus estimate of ($2.25) by $0.25.

Institutional Trading of Adial Pharmaceuticals

An institutional investor recently raised its position in Adial Pharmaceuticals stock. Jane Street Group LLC lifted its holdings in shares of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 887.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 121,841 shares of the company’s stock after purchasing an additional 109,500 shares during the period. Jane Street Group LLC owned about 10.97% of Adial Pharmaceuticals worth $27,000 as of its most recent SEC filing. 16.41% of the stock is owned by hedge funds and other institutional investors.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.